방사선 종양학 시장 : 기술별, 구성 요소별, 투여 방법별, 용도별, 최종사용자별 - 세계 시장 예측(2026-2032년)

The Radiation Oncology Market is projected to grow by USD 28.13 billion at a CAGR of 9.04% by 2032.

Radiation Oncology Executive Summary for Providers

Radiation oncology is a core pillar of multidisciplinary cancer care, with radiotherapy used for curative, adjuvant, neoadjuvant, and palliative treatment across common solid tumors. The International Agency for Research on Cancer reported about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022 and projects more than 35 million new cases by 2050, reinforcing sustained demand for radiation therapy capacity.

Growth in radiation oncology is being shaped by adoption of IMRT, IGRT, SBRT, brachytherapy, proton therapy, adaptive radiotherapy, and AI-enabled treatment planning. For providers, the strategic priority is no longer equipment acquisition alone; it is building high-throughput, quality-assured radiation oncology programs that improve access, precision, patient experience, and clinical outcomes.

Transformative Shifts in the Radiation Oncology Landscape

The radiation oncology landscape is shifting from hardware-centered modernization to digitally coordinated cancer care. Linear accelerator replacement cycles increasingly emphasize image guidance, motion management, stereotactic capability, and interoperability with oncology information systems, treatment planning systems, imaging archives, and electronic health records.

Clinical practice is also moving toward hypofractionation, precision dose delivery, and multidisciplinary pathways. Shorter treatment courses can improve patient convenience and department capacity, while advanced techniques such as SBRT and adaptive radiotherapy require stronger physics support, quality assurance, staff training, and evidence-based patient selection.

Cumulative Impact of Artificial Intelligence in Radiation Oncology

Artificial intelligence is increasingly relevant across radiation oncology workflows, including image segmentation, organ-at-risk contouring, treatment plan optimization, quality checks, adaptive replanning, scheduling, and outcomes analytics. Its cumulative value lies in reducing repetitive workload, improving consistency, and enabling clinicians to focus on complex decision-making.

AI must be deployed with governance, validation, cybersecurity controls, and human oversight. Because radiotherapy errors can have serious consequences, leaders should align AI adoption with AAPM, ASTRO, ESTRO, and local regulatory expectations, using prospective monitoring, bias assessment, and performance audits before scaling AI-driven clinical workflows.

Key Regional Insights Across Global Radiation Oncology

North America remains a leading radiation oncology market due to high cancer screening uptake, mature reimbursement, advanced clinical trial networks, and broad availability of IMRT, IGRT, SBRT, proton therapy, and brachytherapy across the United States and Canada. Europe benefits from established cancer plans, cross-border research collaboration, guideline-driven care, and strong public health systems, although radiotherapy capacity, modernization pace, and waiting times vary by country.

Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, and Australia invest in oncology infrastructure, digital treatment planning, image-guided radiotherapy, and advanced radiotherapy techniques to address a large and aging cancer population. Latin America shows rising demand for radiation therapy, with Brazil and Mexico acting as major service hubs, but access remains uneven between large urban centers and underserved rural areas. The Middle East, especially Gulf markets, is building specialized cancer centers and adopting advanced oncology technologies, while Africa faces the largest access gaps, making workforce development, equipment financing, maintenance models, and service sustainability critical to improving radiotherapy availability.

Key Group Insights for Radiation Oncology Market Strategy

The G7 leads in installed radiotherapy capacity, clinical evidence generation, reimbursement sophistication, and adoption of advanced modalities such as SBRT, adaptive radiotherapy, proton therapy, and AI-assisted planning. The European Union supports harmonized cancer policy, research funding, radiotherapy quality frameworks, and cross-border clinical collaboration, while NATO countries often overlap with high-income markets where resilience, cybersecurity, medical supply continuity, and protection of digital oncology infrastructure are increasing strategic priorities.

BRICS markets account for a large share of future cancer burden and represent major opportunities for linear accelerators, treatment planning software, oncology information systems, and training partnerships. ASEAN countries are improving cancer infrastructure at different speeds, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines showing varied capacity needs linked to population distribution, reimbursement models, and specialist availability. GCC countries are investing in premium cancer centers, proton therapy evaluation, digital oncology systems, and international clinical partnerships aligned with national health transformation agendas.

Key Country Insights in Radiation Oncology

The United States is a benchmark market for advanced radiotherapy, value-based care experimentation, clinical trials, and technology adoption, while Canada emphasizes publicly funded access, provincial capacity planning, and evidence-based implementation. Mexico and Brazil face growing cancer demand and opportunities for public-private investment in radiotherapy infrastructure, whereas the United Kingdom, Germany, France, Italy, and Spain remain major European radiotherapy markets with strong guideline-driven care, national cancer strategies, and ongoing modernization programs. Russia maintains significant oncology infrastructure needs across a large geography, requiring continued attention to equipment availability, workforce distribution, and regional access.

China and India are central to future radiation oncology expansion because of population scale, rising cancer incidence, and ongoing hospital investment in linear accelerators, imaging systems, and cancer center capacity. Japan and South Korea are leaders in precision radiotherapy, imaging integration, quality assurance, and technology adoption, supported by advanced hospital networks and aging populations with high cancer care needs. Australia combines strong clinical governance with advanced treatment availability across major metropolitan centers, while also addressing geographic access challenges through networked oncology services and referral pathways.

Actionable Recommendations for Radiation Oncology Leaders

Industry leaders should prioritize capacity models that match cancer incidence, referral patterns, staffing, machine utilization, treatment complexity, and expected maintenance requirements. Investment decisions should evaluate total cost of ownership, uptime, service support, cybersecurity, interoperability, clinical workflow impact, and reimbursement alignment rather than headline equipment specifications alone.

Providers should standardize contouring, treatment planning, peer review, image guidance protocols, incident learning, and quality assurance to support safe scaling of advanced techniques. Partnerships with academic centers, technology suppliers, professional societies, and public health agencies can accelerate workforce training, AI validation, remote planning support, maintenance resilience, and equitable access to modern radiation oncology services.

Research Methodology for Radiation Oncology Analysis

This executive summary is based on secondary research from recognized public and professional sources, including IARC and WHO cancer statistics, national cancer plans, peer-reviewed oncology literature, clinical society guidance, regulatory information, and publicly available health infrastructure data. Insights are synthesized to reflect validated trends in radiotherapy demand, technology adoption, access gaps, clinical workflow modernization, and regional radiation oncology development.

The methodology emphasizes triangulation across epidemiology, installed-capacity indicators, reimbursement context, clinical practice patterns, regulatory direction, workforce requirements, and technology roadmaps. Qualitative interpretation is used only where supported by consistent evidence from credible sources, ensuring the analysis remains data-backed, transparent, and relevant for executive decision-making.

Conclusion: The Future of Radiation Oncology

Radiation oncology is entering a period of accelerated modernization driven by rising global cancer incidence, demand for precision treatment, hypofractionated care pathways, and the integration of AI-enabled clinical workflows. The strongest organizations will be those that combine advanced technology with disciplined quality assurance, workforce development, cybersecurity readiness, and patient-centered access strategies.

As cancer burden rises toward 2050, radiotherapy capacity will remain essential to sustainable oncology care. Leaders that invest in scalable infrastructure, interoperable software, validated AI, robust clinical governance, and equitable service models will be best positioned to improve outcomes and capture long-term market opportunity without compromising safety or quality.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Radiation Oncology Market, by Technology

• 7.1. Brachytherapy
  • 7.1.1. High Dose Rate
  • 7.1.2. Low Dose Rate
• 7.2. Intensity Modulated Radiation Therapy
  • 7.2.1. Step And Shoot Imrt
  • 7.2.2. Volumetric Modulated Arc Therapy
• 7.3. Proton Therapy
  • 7.3.1. Passive Scattering
  • 7.3.2. Pencil Beam Scanning
• 7.4. Stereotactic Body Radiotherapy
  • 7.4.1. Cyberknife
  • 7.4.2. Linac Based
• 7.5. Three Dimensional Conformal Radiation Therapy

8. Radiation Oncology Market, by Component

• 8.1. Hardware
• 8.2. Services
• 8.3. Software

9. Radiation Oncology Market, by Delivery Mode

• 9.1. External Beam
  • 9.1.1. Rotational Beam
  • 9.1.2. Stationary Beam
• 9.2. Intraoperative
  • 9.2.1. Minimally Invasive
  • 9.2.2. Open Surgery

10. Radiation Oncology Market, by Application

• 10.1. Breast Cancer
• 10.2. Head And Neck Cancer
• 10.3. Lung Cancer
• 10.4. Prostate Cancer

11. Radiation Oncology Market, by End User

• 11.1. Ambulatory Surgical Centers
  • 11.1.1. Freestanding
  • 11.1.2. Hospital Affiliated
• 11.2. Cancer Treatment Centers
  • 11.2.1. Multispecialty
  • 11.2.2. Standalone
• 11.3. Hospitals
  • 11.3.1. Private
  • 11.3.2. Public

12. Radiation Oncology Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Radiation Oncology Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Radiation Oncology Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Accuray Incorporated
• 16.2. Becton, Dickinson and Company
• 16.3. Bionix LLC
• 16.4. BrainLab AG
• 16.5. Canon Inc.
• 16.6. Carl Zeiss AG
• 16.7. Eckert and Ziegler AG
• 16.8. Elekta AB
• 16.9. GE HealthCare Technologies Inc.
• 16.10. Hitachi, Ltd.
• 16.11. Hologic, Inc.
• 16.12. IntraOp Medical, Inc.
• 16.13. Ion Beam Applications S.A.
• 16.14. Isoray Inc.
• 16.15. Koninklijke Philips N.V.
• 16.16. Nordion Inc.
• 16.17. Optivus Proton Therapy, Inc.
• 16.18. P-Cure LTD.
• 16.19. Panacea Medical Technologies Pvt. LTD.
• 16.20. Provision Healthcare, LLC
• 16.21. Siemens Healthineers AG
• 16.22. Stryker Corporation
• 16.23. Sumitomo Heavy Industries, LTD
• 16.24. Theragenics Corporation
• 16.25. ViewRay, Inc.